Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc has strengthened its financial position through equity financings and option exercises, leading to increased financing income of $284K for the quarter and $611K year-to-date, significantly higher than the previous year. The company is poised for substantial growth with the anticipated full launch of its LIBERTY Endovascular Robotic System in the U.S. in 2Q26, along with further introductions in the EU and other markets, supported by expanded commercial capabilities and positive provider feedback. Additionally, the implementation of a logistics partnership enhances operational readiness, positioning Microbot favorably for accelerated growth and a competitive market advantage.

Bears say

Microbot Medical Inc faces significant risks that contribute to a negative outlook on its stock, including potential delays in the commercialization of its LIBERTY Endovascular Robotic System and challenges in expanding into neuro and cardio markets. The company may experience headwinds related to reimbursement issues and the absence of profitability in the near term, exacerbated by the high cost of the device impacting hospital margins. Additionally, the lack of data from randomized controlled trials and setbacks in securing international regulatory approvals could hinder the company's growth and market adoption.

Microbot Medical (MBOT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.